Health-related quality of life, one-year costs and economic evaluation in extracorporeal membrane oxygenation in critically ill adults

Standard

In: Journal of critical care, Vol. 73, 154215, 01.02.2023.

Research output: Contribution to journal › Article › Academic › peer-review

BibTeX

@article{5118330a211346949d6116ca37554239,

title = "Health-related quality of life, one-year costs and economic evaluation in extracorporeal membrane oxygenation in critically ill adults",

abstract = "Purpose: This study reports on survival and health related quality of life (HRQOL) after extracorporeal membrane oxygenation (ECMO) treatment and the associated costs in the first year. Materials and Methods: Prospective observational cohort study patients receiving ECMO in the intensive care unit during August 2017 and July 2019. We analyzed all healthcare costs in the first year after index admission. Follow-up included a HRQOL analysis using the EQ-5D-5L at 6 and 12 months. Results: The study enrolled 428 patients with an ECMO run during their critical care admission. The one-year mortality was 50%. Follow up was available for 124 patients at 12 months. Survivors reported a favorable mean HRQOL (utility) of 0.71 (scale 0–1) at 12 months of 0.77. The overall health status (VAS, scale 0–100) was reported as 73.6 at 12 months. Mean total costs during the first year were $204,513 ± 211,590 with hospital costs as the major factor contributing to the total costs. Follow up costs were $53,752 ± 65,051 and costs of absenteeism were $7317 ± 17,036. Conclusions: At one year after hospital admission requiring ECMO the health-related quality of life is favorable with substantial costs but considering the survival might be acceptable. However, our results are limited by loss of follow up. So it may be possible that only the best-recovered patients returned their questionnaires. This potential bias might lead to higher costs and worse HRQOL in a real-life scenario.",

keywords = "Cost analysis, Critical care, Extracorporeal life support, Hospital costs, Outcome, Quality of life",

author = "{Oude Lansink-Hartgring}, Annemieke and Miranda, {Dinis Dos Reis} and Loes Mandigers and Thijs Delnoij and Roberto Lorusso and Maas, {Jacinta J.} and {Elzo Kraemer}, {Carlos V.} and Vlaar, {Alexander P. J.} and Raasveld, {S. Jorinde} and Donker, {Dirk W.} and Erik Scholten and Anja Balzereit and {van den Brule}, Judith and Marijn Kuijpers and {On behalf of the DUTCH ECLS Study Group} and Vermeulen, {Karin M.} and {van den Bergh}, {Walter M.}",

note = "Funding Information: We would like to thank the research nurses and research coordinator from the critical care department of the UMCG for their support. Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2023",

month = feb,

day = "1",

doi = "10.1016/j.jcrc.2022.154215",

language = "English",

volume = "73",

journal = "Journal of critical care",

issn = "0883-9441",

publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Health-related quality of life, one-year costs and economic evaluation in extracorporeal membrane oxygenation in critically ill adults

AU - Oude Lansink-Hartgring, Annemieke

AU - Miranda, Dinis Dos Reis

AU - Mandigers, Loes

AU - Delnoij, Thijs

AU - Lorusso, Roberto

AU - Maas, Jacinta J.

AU - Elzo Kraemer, Carlos V.

AU - Vlaar, Alexander P. J.

AU - Raasveld, S. Jorinde

AU - Donker, Dirk W.

AU - Scholten, Erik

AU - Balzereit, Anja

AU - van den Brule, Judith

AU - Kuijpers, Marijn

AU - On behalf of the DUTCH ECLS Study Group

AU - Vermeulen, Karin M.

AU - van den Bergh, Walter M.

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Purpose: This study reports on survival and health related quality of life (HRQOL) after extracorporeal membrane oxygenation (ECMO) treatment and the associated costs in the first year. Materials and Methods: Prospective observational cohort study patients receiving ECMO in the intensive care unit during August 2017 and July 2019. We analyzed all healthcare costs in the first year after index admission. Follow-up included a HRQOL analysis using the EQ-5D-5L at 6 and 12 months. Results: The study enrolled 428 patients with an ECMO run during their critical care admission. The one-year mortality was 50%. Follow up was available for 124 patients at 12 months. Survivors reported a favorable mean HRQOL (utility) of 0.71 (scale 0–1) at 12 months of 0.77. The overall health status (VAS, scale 0–100) was reported as 73.6 at 12 months. Mean total costs during the first year were $204,513 ± 211,590 with hospital costs as the major factor contributing to the total costs. Follow up costs were $53,752 ± 65,051 and costs of absenteeism were $7317 ± 17,036. Conclusions: At one year after hospital admission requiring ECMO the health-related quality of life is favorable with substantial costs but considering the survival might be acceptable. However, our results are limited by loss of follow up. So it may be possible that only the best-recovered patients returned their questionnaires. This potential bias might lead to higher costs and worse HRQOL in a real-life scenario.

AB - Purpose: This study reports on survival and health related quality of life (HRQOL) after extracorporeal membrane oxygenation (ECMO) treatment and the associated costs in the first year. Materials and Methods: Prospective observational cohort study patients receiving ECMO in the intensive care unit during August 2017 and July 2019. We analyzed all healthcare costs in the first year after index admission. Follow-up included a HRQOL analysis using the EQ-5D-5L at 6 and 12 months. Results: The study enrolled 428 patients with an ECMO run during their critical care admission. The one-year mortality was 50%. Follow up was available for 124 patients at 12 months. Survivors reported a favorable mean HRQOL (utility) of 0.71 (scale 0–1) at 12 months of 0.77. The overall health status (VAS, scale 0–100) was reported as 73.6 at 12 months. Mean total costs during the first year were $204,513 ± 211,590 with hospital costs as the major factor contributing to the total costs. Follow up costs were $53,752 ± 65,051 and costs of absenteeism were $7317 ± 17,036. Conclusions: At one year after hospital admission requiring ECMO the health-related quality of life is favorable with substantial costs but considering the survival might be acceptable. However, our results are limited by loss of follow up. So it may be possible that only the best-recovered patients returned their questionnaires. This potential bias might lead to higher costs and worse HRQOL in a real-life scenario.

KW - Cost analysis

KW - Critical care

KW - Extracorporeal life support

KW - Hospital costs

KW - Outcome

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85142259784&partnerID=8YFLogxK

U2 - 10.1016/j.jcrc.2022.154215

DO - 10.1016/j.jcrc.2022.154215

M3 - Article

C2 - 36402123

VL - 73

JO - Journal of critical care

JF - Journal of critical care

SN - 0883-9441

M1 - 154215

ER -

ID: 27501111

Generic Portal